-
Pyruvate kinase deficiency (PKD) disease correction therapy! EU approves the first oral PK allosteric activator Pyrukynd (mitapivat)!
Time of Update: 2022-11-26
Nov. 12, 2022 /Biovalley BIOON/ -- Agios Pharmaceuticals has announced that the European Commission (EC) has approved Pyrukynd (mitapivat) for the treatment of adult patients with pyruvate kinase deficiency (PKD).
-
Data from the world's first phase III study of oral TYK2 allosteric inhibitor deuscravacitinib in Asian populations were released
Time of Update: 2022-09-21
13, 2022 /PRNewswire/ -- Bristol-Myers Squibb presented the results of the key Phase III study of POTYK PSO-3 at the recent 2022 European Society of Dermatology and Venereal Diseases Annual Meeting (EADV), confirming that in Asian patients with moderate to severe plaque psoriasis, mainly in China The world's first oral tyrosine kinase 2 (TYK2) allosteric inhibitor, deuscravacitinib, has significantly long-lasting benefits, is well tolerated for safety, and has also shown therapeutic advantages in refractory sites (scalp).
-
Nat Cancer: JBJ-09-063: Potential EGFR Allosteric Inhibitors for Non-Small Cell Lung Cancer Treatment
Time of Update: 2022-05-20
Previous studies have shown that EGFR-based small-molecule tyrosine kinase inhibitor (TKI) therapy has a certain therapeutic effect in patients with EGFR-mutant lung cancer, but it is usually accompanied by the emergence of drug resistance .
-
Double-depth PCA: finding key allosteric sites in human proteins
Time of Update: 2022-04-26
An allosteric effect occurs when a molecule binds to a protein surface, which in turn causes changes in the protein's distant location to regulate its function by "remote control" .
-
FDA approves GABA receptor allosteric modulator ganaxolone
Time of Update: 2022-04-21
S. Food and Drug Administration has approved Ztalmy (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency (CDD) in patients over two years of age .
-
Nuocheng Jianhua TYK2 JH2 allosteric inhibitor new drug research application was accepted by the State Food and Drug Administration
Time of Update: 2022-01-09
On December 28, Nuocheng Jianhua announced that the company's self-developed TYK2 JH2 allosteric inhibitor ICP-488 New Drug Research (IND) application has been accepted by the National Medical Products Administration (NMPA) .
Factor-driven cell signal transduction, thereby inhibiting the pathological process of autoimmunity and inflammation .
-
Cong Yao's research group reveals the allosteric and substrate recognition mechanism of the proteasome induced by the ubiquitin chain
Time of Update: 2022-01-07
This study analyzed the near-atomic resolution cryo-EM structure of a series of proteasomes in the presence of K48-Ub 4 ubiquitin chains, and for the first time captured the three-dimensional structure of the proteasome bound to K48-Ub 4 ubiquitin chains, revealing the ubiquitin chain The molecular mechanism that regulates the proteasome's recognition of ubiquitinated substrates and triggers substrate degradation provides a key structural basis for the ultimate elucidation of the mechanism of proteasome degradation of ubiquitinated substrates under physiological conditions .
-
Huazhong University of Science and Technology published a paper: A new mechanism for allosteric
Time of Update: 2021-12-28
On December 6, the internationally renowned journal eLife published an online publication titled "Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface" by Professor Liu Jianfeng’s team from the School of Life Science and Technology, Huazhong University of Science and Technology.
-
Wang Jiangyun/Liu Zhijie/Hua Tian's group has made important progress in the research of GPCR allosteric regulation mechanism
Time of Update: 2021-10-22
On October 1, 2021, the Journal of the American Chemical Society published an online publication titled "A Genetically Encoded F-19 NMR Probe Reveals the Allosteric Modulation Mechanism of Cannabinoi
-
Hello, Watson and Crick, I’m Hoogsteen-the development of a triple helix-based DNA allosteric device
Time of Update: 2021-10-21
Design of DNA allosteric element-Z-switch based on triple helix .
This study expands the application of allosteric regulation in nucleic acid nanostructures, establishes a new regulation model, establishes the screening process, and enriches the regulation mechanism and completion methods.
-
to allosteric activation, which promotes weight gain and the development of diabetes.
Time of Update: 2021-10-20
001 compared with wild-type enzyme, or, when indicated in brackets, compared with 3 mmol/l glucose stimulation (ANOVA/Bonferroni)Figure 3 Intracellular localization and insulin secretion of Dendra2-GK variants .
-
Express GABA receptor allosteric modulator is eligible for priority review, significantly reducing the frequency of seizures
Time of Update: 2021-10-11
S. FDA has granted priority review status for its new drug application (NDA) for its GABAA receptor positivity modulator, ganaxolone, to treat epileptic seizures related to CDKL5 deficiency (CDD) .
-
GABA receptor allosteric modulator receives priority review qualification, significantly reduces seizure frequency
Time of Update: 2021-09-28
S. FDA has granted its GABAA receptor positive sex structure modulator ganaxolone a new drug application (NDA) priority review to treat epileptic seizures related to CDKL5 deficiency (CDD) .
Reference materials:[1] Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder.
-
Nature: Positive allosteric modulator (PAM) is expected to become a new non-opioid analgesic
Time of Update: 2021-09-11
Neuropathic painIn this study, researchers used electrophysiology and preclinical pain models to verify that a special class of molecules, called " positive allosteric modulators " ( PAM ), can bind to different regions of the A1 receptor to provide Selectively target the A1 receptor .
-
Potential "first-in-class" allosteric activator received priority review qualification
Time of Update: 2021-09-05
Today, Agios Pharmaceuticals announced that the US FDA has accepted the new drug application (NDA) submitted by the company for mitapivat for the treatment of adult patients with pyruvate kinase (PK) deficiency .